Key facts
- China has proposed revisions to government procurement and project bidding laws.
- The revisions aim to eliminate discriminatory practices against foreign and private companies.
- The draft legislation was submitted to the top legislature in late June.
- The goal is to ensure equal participation for all suppliers.
- Chinese regulators have removed over 10 drug and medical-device companies from national bulk-procurement programs.
- Disqualifications were due to serious production or quality-management defects.
- Shandong Beida Gaoke Huatai Pharmaceutical Co. is among the disqualified companies.
- The company's amiodarone hydrochloride injection production line was suspended.
China has put forward revisions to its government procurement and project bidding laws, with the intention of eliminating discriminatory practices that have previously disadvantaged foreign and private companies. The draft legislation was submitted to the country's top legislative body in late June. The proposed changes are designed to create a more equitable environment, ensuring that all suppliers have an equal opportunity to participate in government contracts and projects. This initiative signals a potential shift towards a more open and fair procurement system within China.
In a separate development concerning procurement, Chinese regulators have taken action against more than 10 drug and medical-device companies. These companies have been removed from national bulk-procurement programs as a consequence of serious defects found in their production processes or quality-management systems. One specific instance cited involves Shandong Beida Gaoke Huatai Pharmaceutical Co., which faced a suspension of its production line for amiodarone hydrochloride injection due to identified quality issues. These disqualifications highlight ongoing efforts by Chinese authorities to enforce standards and ensure the safety and efficacy of medical products available through public procurement channels.